NEW YORK, Dec. 21, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Diplomat Pharmacy, Inc. securities (NYSE:DPLO) from October 9, 2014 through November 2, 2016, both dates inclusive (the “Class Period”) of the important January 9, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Diplomat Pharmacy investors under the federal securities laws.
To join the Diplomat Pharmacy class action, go to http://www.rosenlegal.com/cases-992.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Diplomat Pharmacy lacked adequate internal controls over its financial reporting; (2) therefore, Diplomat Pharmacy could not adequately calculate DIR fees; (3) Diplomat Pharmacy’s hepatitis C segment was not performing as previously disclosed to investors; (4) as such, Diplomat Pharmacy had overstated its full-year 2016 guidance; and (5) as a result, Defendants’ statements about Diplomat Pharmacy’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 9, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-992.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
OpenAI Explores Massive Funding Round at $750 Billion Valuation
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 



